StockData
MBX Biosciences, Inc. logo

MBX Biosciences, Inc. (MBX) stock

MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$53.10−0.02 (-0.04%)

Close on Nov 17, 2026Market cap $2.56BP/E –Yield –

MBX Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

MBX Biosciences's operating income for the twelve months ending Sep 30, 2026 was -$160.33M. For fiscal 2025 it was -$98.06M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$98.06M–
FY2024Dec 31, 2024-$68.19M–
FY2023Dec 31, 2023-$35.31M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$66.34M–
Q2 FY2026Jun 30, 2026-$40.93M–
Q1 FY2026Mar 31, 2026-$27.27M–
Q4 FY2025Dec 31, 2025-$25.80M–
Q3 FY2025Sep 30, 2025-$23.93M–
Q2 FY2025Jun 30, 2025-$21.81M–
Q1 FY2025Mar 31, 2025-$26.53M–
Q4 FY2024Dec 31, 2024-$18.61M–
Q3 FY2024Sep 30, 2024-$19.61M–
Q2 FY2024Jun 30, 2024-$16.66M–
Q1 FY2024Mar 31, 2024-$13.31M–
Q4 FY2023Dec 31, 2023-$9.99M–
Q3 FY2023Sep 30, 2023-$10.95M–

More MBX Biosciences figures

See a number that looks wrong?